Axsome Therapeutics enrolled the first patient in its MOMENTUM study, a Phase 3, randomized, controlled trial assessing the efficacy and safety of AXS-07 in the acute treatment of migraine. MOMENTUM will enroll only patients with a history of inadequate response to prior migraine treatments. Topline results from this trial are expected in Q1 of 2020.
https://thefly.com/landingPageNews.php?id=2873537
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.